2019
Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer?
Buckley L, Suarez‐Almazor M. Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer? Arthritis & Rheumatology 2019, 71: 1971-1973. PMID: 31379056, DOI: 10.1002/art.41064.Peer-Reviewed Original Research
2017
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis & Rheumatology 2017, 69: 1521-1537. PMID: 28585373, DOI: 10.1002/art.40137.Peer-Reviewed Original ResearchConceptsOral bisphosphonate treatmentGlucocorticoid-induced osteoporosisVitamin DGC treatmentAntifracture medicationsBisphosphonate treatmentFracture riskGC usersHigh-dose GC treatmentLong-term glucocorticoid treatmentLong-term GC treatmentSpecial populationsHarms of interventionsHigh fracture riskLower fracture riskQuality of evidenceGeneral adult populationBisphosphonate regimenGIOP preventionOral bisphosphonatesOsteoporosis medicationsRheumatology guidelinesDenosumab treatmentLifestyle modificationRecommendations Assessment
2016
Thromboelastography in the Characterization of Coagulation Status in Antiphospholipid Syndrome
Wallace N, Dumont A, Burns A, Christopher T, Rinder H, Kriegel M, Buckley L, Erkan D, Lee A. Thromboelastography in the Characterization of Coagulation Status in Antiphospholipid Syndrome. Blood 2016, 128: 4983. DOI: 10.1182/blood.v128.22.4983.4983.Peer-Reviewed Original ResearchLupus anticoagulant-hypoprothrombinemia syndromePartial thromboplastin timeAntiphospholipid syndromeImmune thrombocytopeniaAntiphospholipid antibodiesAPS patientsProthrombin timeCessation of anticoagulationGlycoprotein 1 antibodiesObstetrical antiphospholipid syndromeRole of thromboelastographySevere hemorrhagic complicationsSpecific coagulation defectsCatastrophic antiphospholipid syndromeChronic liver diseaseGlobal hemostasis assaysTraditional laboratory markersBaseline prolongationChronic aspirinPersistent positivityAdrenal hemorrhageAnticardiolipin antibodiesHemorrhagic complicationsImmunomodulatory treatmentAnticardiolipin IgG
2009
Reply
Desai S, Solomon D, Abramson S, Buckley L, Crofford L, Cush J, Lovell D, Saag K, Drugs A. Reply. Arthritis & Rheumatism 2009, 61: 285-286. DOI: 10.1002/art.24171.Peer-Reviewed Original Research
2001
Worsening of Macrophage Activation Syndrome in a Patient with Adult Onset Still’s Disease after Initiation of Etanercept Therapy
Stern A, Riley R, Buckley L. Worsening of Macrophage Activation Syndrome in a Patient with Adult Onset Still’s Disease after Initiation of Etanercept Therapy. JCR Journal Of Clinical Rheumatology 2001, 7: 252-256. PMID: 17039144, DOI: 10.1097/00124743-200108000-00013.Peer-Reviewed Original ResearchMacrophage activation syndromeActivation syndromeSoluble tumor necrosis factor-alpha receptorEpstein-Barr virus infectionNonsteroidal anti-inflammatory drugsChildhood rheumatic disordersDramatic clinical improvementUse of etanerceptTumor necrosis factor-alpha receptorPeriod of feverAnti-inflammatory drugsEtanercept therapyClinical improvementPulse corticosteroidsLymph nodesParenteral goldRheumatic disordersClinical syndromeHistopathological examinationAdult onsetVirus infectionInfectious processPharmacological agentsBone marrowMononuclear phagocytes
2000
Obstacles to Promotion? Values of Women Faculty about Career Success and Recognition
Buckley L, Sanders K, Shih M, Kallar S, Hampton C. Obstacles to Promotion? Values of Women Faculty about Career Success and Recognition. Academic Medicine 2000, 75: 283-288. PMID: 10724319, DOI: 10.1097/00001888-200003000-00021.Peer-Reviewed Original Research
1999
Prevention of corticosteroid‐induced osteoporosis: Results of a patient survey
Buckley L, Marquez M, Feezor R, Ruffin D, Benson L. Prevention of corticosteroid‐induced osteoporosis: Results of a patient survey. Arthritis & Rheumatism 1999, 42: 1736-1739. PMID: 10446875, DOI: 10.1002/1529-0131(199908)42:8<1736::aid-anr24>3.0.co;2-e.Peer-Reviewed Original ResearchConceptsBone density testingCorticosteroid-induced osteoporosisCorticosteroid treatmentPreventive treatmentLong-term oral corticosteroid treatmentLong-term corticosteroid usersLong-term corticosteroid treatmentDensity testingMean prednisone doseOral corticosteroid treatmentBone density testHormone replacement therapyPrimary care physiciansStandard of careCorticosteroid usersPMP womenPrednisone dosePostmenopausal womenBisphosphonate treatmentCare physiciansOsteoporosis preventionBone lossReplacement therapyCalcium supplementsPatient survey
1998
Perceptions of Pharmacists about Adverse Effects of Corticosteroid Therapy: Focus on Osteoporosis
Hudson J, Small R, Buckley L. Perceptions of Pharmacists about Adverse Effects of Corticosteroid Therapy: Focus on Osteoporosis. Journal Of The American Pharmacists Association 1998, 38: 710-716. PMID: 9861789, DOI: 10.1016/s1086-5802(16)30392-8.Peer-Reviewed Original ResearchConceptsCorticosteroid therapyPerceptions of pharmacistsCorticosteroid usePostmenopausal womenPremenopausal womenAdverse effectsPatient counselingHigh-dose corticosteroid useWeight gainCorticosteroid-induced osteoporosisHigh-dose corticosteroidsHigh-dose therapyDrug-induced complicationsPrevention of osteoporosisPrednisone useBone densityOsteoporosisHospital pharmacistsMailed surveyTherapyMood changesPharmacistsWomenRespondents' knowledgeCorticosteroidsVariations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty.
Buckley L, Marquez M, Hudson J, Downs R, Vacek P, Small R, Poses R. Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty. The Journal Of Rheumatology 1998, 25: 2195-202. PMID: 9818664.Peer-Reviewed Original ResearchConceptsEstrogen replacement therapyCorticosteroid treatmentPhysician judgmentCorticosteroid usePhysician specialtySide effectsPostmenopausal patientsVitamin DBone lossReplacement therapyCorticosteroid-induced osteoporosisImportance of osteoporosisVitamin D supplementationMajority of patientsRisk of osteoporosisPrimary care physiciansSignificant side effectsHypothetical clinical scenariosImportance of corticosteroidsEfficacy of treatmentD supplementationPostmenopausal womenPremenopausal womenPhysician assessmentCare physicians
1997
A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group.
Tuttleman M, Pillemer S, Tilley B, Fowler S, Buckley L, Alarcón G, Trentham D, Neuner R, Clegg D, Leisen J, Heyse S. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group. The Journal Of Rheumatology 1997, 24: 1910-5. PMID: 9330931.Peer-Reviewed Original ResearchConceptsPatient global assessmentSF-36Rheumatoid arthritisM-HAQOutcome measuresClinical trialsGlobal assessmentShort Form Health SurveyFunctional health status measuresJoint swelling scoreRA clinical trialsRA outcome measuresHealth Assessment QuestionnaireHealth status instrumentsSF-36 scalesRheumatoid arthritis trialsHealth status measuresMultitrait scaling analysisCross-sectional assessmentCross-sectional analysisMIRA trialStudy patientsRA populationScore correlationsPain itemsImportance of guidelines on glucocorticoid‐induced osteoporosis: Comment on the American college of rheumatology recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis
Buckley L. Importance of guidelines on glucocorticoid‐induced osteoporosis: Comment on the American college of rheumatology recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis. Arthritis & Rheumatism 1997, 40: 1547-1547. PMID: 9259442, DOI: 10.1002/art.1780400829.Peer-Reviewed Original ResearchEffects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis.
Buckley L, Leib E, Cartularo K, Vacek P, Cooper S. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. The Journal Of Rheumatology 1997, 24: 1489-94. PMID: 9263140.Peer-Reviewed Original ResearchConceptsBone mineral densityLow-dose methotrexateRheumatoid arthritisLumbar spineFemoral neckDose methotrexateMineral densityBMD of patientsFemoral neck bone mineral densityNeck bone mineral densitySpine bone mineral densityMeasurement of BMDAntirheumatic drug useVitamin D3 supplementationYears of followupGreater bone lossDMARD useD3 supplementationFollowup visitMTX useBone lossPrednisoneSimilar dosePatientsMethotrexatePrevention of Corticosteroid-Induced Osteoporosis
Buckley L. Prevention of Corticosteroid-Induced Osteoporosis. Annals Of Internal Medicine 1997, 127: 90. DOI: 10.7326/0003-4819-127-1-199707010-00026.Peer-Reviewed Original ResearchRadiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) Trial.
Bluhm G, Sharp J, Tilley B, Alarcon G, Cooper S, Pillemer S, Clegg D, Heyse S, Trentham D, Neuner R, Kaplan D, Leisen J, Buckley L, Duncan H, Tuttleman M, Li S, Fowler S. Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) Trial. The Journal Of Rheumatology 1997, 24: 1295-302. PMID: 9228128.Peer-Reviewed Original ResearchConceptsJoint space narrowingRheumatoid arthritis trialsDisease progressionArthritis trialsSpace narrowingPercentage of patientsSignificant differencesReported clinical resultsErosive jointsOral minocyclinePlacebo groupErosive diseaseFinal visitRadiographic progressionPlacebo treatmentTreat analysisRadiographic resultsFuture trialsClinical centersClinical resultsPosteroanterior filmsRadiographic changesTreatment benefitProgression rateWeek trialMultiple congenital anomalies associated with weekly low‐dose methotrexate treatment of the mother
Buckley L, Bullaboy C, Leichtman L, Marquez M. Multiple congenital anomalies associated with weekly low‐dose methotrexate treatment of the mother. Arthritis & Rheumatism 1997, 40: 971-973. PMID: 9153561, DOI: 10.1002/art.1780400527.Peer-Reviewed Original ResearchConceptsWeekly low-dose methotrexateLow-dose methotrexateMultiple congenital anomaliesCongenital anomaliesLow-dose MTX treatmentLow-dose methotrexate treatmentJuvenile rheumatoid arthritisFirst case reportGroup of abnormalitiesMultiple congenital abnormalitiesMethotrexate treatmentMTX treatmentRheumatoid arthritisFirst trimesterCase reportMaternal ingestionSpontaneous abortionCongenital abnormalitiesMethotrexateDosage levelsAbnormalitiesMothersAbortionTreatmentReport
1996
Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial.
Buckley L, Leib E, Cartularo K, Vacek P, Cooper S. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Annals Of Internal Medicine 1996, 125: 961-8. PMID: 8967706, DOI: 10.7326/0003-4819-125-12-199612150-00004.Peer-Reviewed Original ResearchConceptsBone mineral densityLow-dose corticosteroidsPlacebo-controlled trialVitamin D3 supplementationMineral densityRheumatoid arthritisVitamin D3Prednisone therapyLumbar spineD3 supplementationBone lossOutpatient care facilitiesLong-term useCorticosteroid useVertebral fracturesWard's triangleAutoimmune diseasesFemoral neckCorticosteroidsHigh riskSupplemental calciumRational therapyPatientsArthritisTherapyPrevalence of Pulmonary Hypertension in Limited and Diffuse Scleroderma
Battle R, Davitt M, Cooper S, Buckley L, Leib E, Beglin P, Tischler M. Prevalence of Pulmonary Hypertension in Limited and Diffuse Scleroderma. CHEST Journal 1996, 110: 1515-1519. PMID: 8989070, DOI: 10.1378/chest.110.6.1515.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBlood PressureCross-Sectional StudiesEchocardiography, DopplerElectrocardiographyFemaleHumansHypertension, PulmonaryMaleMiddle AgedProspective StudiesPulmonary ArteryPulmonary Diffusing CapacityPulmonary VentilationScleroderma, SystemicTricuspid Valve InsufficiencyConceptsPulmonary artery systolic pressurePulmonary hypertensionDiffuse sclerodermaTricuspid regurgitationSignificant end-organ damageProspective cross-sectional studyTranstricuspid pressure gradientUndiagnosed pulmonary hypertensionEnd-organ damageRight atrial pressureSuccessful treatment strategyCross-sectional studyAtrial pressureMost patientsConsecutive patientsSystolic pressureDoppler echocardiogramOutpatient clinicRespiratory indexClinical signsTreatment strategiesHypertensionPatientsNoninvasive assessmentScleroderma
1995
Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis.
Buckley L, Leib E, Cartularo K, Vacek P, Cooper S. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. The Journal Of Rheumatology 1995, 22: 1055-9. PMID: 7674230.Peer-Reviewed Original ResearchConceptsBone mineral densityRheumatoid arthritisLumbar spineFemoral neckMineral densityLow dosesLow-dose corticosteroid useLow bone mineral densitySimilar bone mineral densityLow-dose corticosteroidsMean daily doseEffect of corticosteroidsCross-sectional studyDose corticosteroidsPrednisone doseCorticosteroid useDisease durationDaily doseDaily dosesSectional studyRisk factorsStudy groupPatientsDisease severityCorticosteroidsMinocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.
Tilley B, Alarcón G, Heyse S, Trentham D, Neuner R, Kaplan D, Clegg D, Leisen J, Buckley L, Cooper S, Duncan H, Pillemer S, Tuttleman M, Fowler S. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Annals Of Internal Medicine 1995, 122: 81-9. PMID: 7993000, DOI: 10.7326/0003-4819-122-2-199501150-00001.Peer-Reviewed Original ResearchConceptsIgM rheumatoid factor levelsErythrocyte sedimentation rateRheumatoid factor levelsRheumatoid arthritisMinocycline groupGlobal assessmentPlacebo groupMore patientsPlatelet countModified Health Assessment QuestionnaireFactor levelsEfficacy of minocyclineEvaluator's global assessmentWeek 48 visitActive rheumatoid arthritisHealth Assessment QuestionnairePatient global assessmentPlacebo-controlled trialModerate rheumatoid arthritisDisease-modifying drugsMechanism of actionJoint tendernessMorning stiffnessStudy medicationDisease activity
1992
Progressive aortic valve inflammation occurring despite apparent remission of relapsing polychondritis
Buckley L, Ades P. Progressive aortic valve inflammation occurring despite apparent remission of relapsing polychondritis. Arthritis & Rheumatism 1992, 35: 812-814. PMID: 1622420, DOI: 10.1002/art.1780350716.Peer-Reviewed Original Research